The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 31, 2017
Filed:
Sep. 17, 2014
Applicant:
Ambit Biosciences Corporation, San Diego, CA (US);
Inventors:
Robert E. Corringham, San Diego, CA (US);
Joyce K. James, San Diego, CA (US);
Patrick B. O'Donnell, San Diego, CA (US);
Assignee:
Ambit Biosciences Corporation, San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5377 (2006.01); A61K 31/429 (2006.01); A61K 9/08 (2006.01); A61K 9/14 (2006.01); A61K 9/16 (2006.01); A61K 9/48 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5377 (2013.01); A61K 9/0053 (2013.01); A61K 9/08 (2013.01); A61K 9/145 (2013.01); A61K 9/1641 (2013.01); A61K 9/4866 (2013.01); A61K 31/429 (2013.01); A61K 45/06 (2013.01);
Abstract
Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.